Literature DB >> 28338320

Inhibitors of Protein Methyltransferases and Demethylases.

H Ümit Kaniskan1, Michael L Martini1, Jian Jin1.   

Abstract

Post-translational modifications of histones by protein methyltransferases (PMTs) and histone demethylases (KDMs) play an important role in the regulation of gene expression and transcription and are implicated in cancer and many other diseases. Many of these enzymes also target various nonhistone proteins impacting numerous crucial biological pathways. Given their key biological functions and implications in human diseases, there has been a growing interest in assessing these enzymes as potential therapeutic targets. Consequently, discovering and developing inhibitors of these enzymes has become a very active and fast-growing research area over the past decade. In this review, we cover the discovery, characterization, and biological application of inhibitors of PMTs and KDMs with emphasis on key advancements in the field. We also discuss challenges, opportunities, and future directions in this emerging, exciting research field.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28338320      PMCID: PMC5610952          DOI: 10.1021/acs.chemrev.6b00801

Source DB:  PubMed          Journal:  Chem Rev        ISSN: 0009-2665            Impact factor:   60.622


  675 in total

1.  Subunit contributions to histone methyltransferase activities of fly and worm polycomb group complexes.

Authors:  Carrie S Ketel; Erica F Andersen; Marcus L Vargas; Jinkyo Suh; Susan Strome; Jeffrey A Simon
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

2.  Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.

Authors:  Veronica Veschi; Zhihui Liu; Ty C Voss; Laurent Ozbun; Berkley Gryder; Chunhua Yan; Ying Hu; Anqi Ma; Jian Jin; Sharlyn J Mazur; Norris Lam; Barbara K Souza; Giuseppe Giannini; Gordon L Hager; Cheryl H Arrowsmith; Javed Khan; Ettore Appella; Carol J Thiele
Journal:  Cancer Cell       Date:  2017-01-09       Impact factor: 31.743

3.  The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.

Authors:  Jun Yang; Adrian M Jubb; Luke Pike; Francesca M Buffa; Helen Turley; Dilair Baban; Russell Leek; Kevin C Gatter; Jiannis Ragoussis; Adrian L Harris
Journal:  Cancer Res       Date:  2010-08-03       Impact factor: 12.701

4.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.

Authors:  Philip Kahl; Lucia Gullotti; Lukas Carl Heukamp; Susanne Wolf; Nicolaus Friedrichs; Roland Vorreuther; Gerold Solleder; Patrick J Bastian; Jörg Ellinger; Eric Metzger; Roland Schüle; Reinhard Buettner
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

5.  Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization.

Authors:  Myles B C Dillon; Daniel A Bachovchin; Steven J Brown; M G Finn; Hugh Rosen; Benjamin F Cravatt; Kerri A Mowen
Journal:  ACS Chem Biol       Date:  2012-04-20       Impact factor: 5.100

6.  Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors.

Authors:  Ralf Heinke; Astrid Spannhoff; Rene Meier; Patrick Trojer; Ingo Bauer; Manfred Jung; Wolfgang Sippl
Journal:  ChemMedChem       Date:  2009-01       Impact factor: 3.466

7.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Authors:  Wendy Béguelin; Relja Popovic; Matt Teater; Yanwen Jiang; Karen L Bunting; Monica Rosen; Hao Shen; Shao Ning Yang; Ling Wang; Teresa Ezponda; Eva Martinez-Garcia; Haikuo Zhang; Yupeng Zheng; Sharad K Verma; Michael T McCabe; Heidi M Ott; Glenn S Van Aller; Ryan G Kruger; Yan Liu; Charles F McHugh; David W Scott; Young Rock Chung; Neil Kelleher; Rita Shaknovich; Caretha L Creasy; Randy D Gascoyne; Kwok-Kin Wong; Leandro Cerchietti; Ross L Levine; Omar Abdel-Wahab; Jonathan D Licht; Olivier Elemento; Ari M Melnick
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

8.  Novel Scaffolds of Cell-Active Histone Demethylase Inhibitors Identified from High-Throughput Screening.

Authors:  Wei Wang; Laura J Marholz; Xiang Wang
Journal:  J Biomol Screen       Date:  2015-04-16

9.  Exploration of cyanine compounds as selective inhibitors of protein arginine methyltransferases: synthesis and biological evaluation.

Authors:  Hao Hu; Eric A Owens; Hairui Su; Leilei Yan; Andrew Levitz; Xinyang Zhao; Maged Henary; Yujun George Zheng
Journal:  J Med Chem       Date:  2015-01-21       Impact factor: 7.446

10.  Protein arginine-methyltransferase-dependent oncogenesis.

Authors:  Ngai Cheung; Li Chong Chan; Alex Thompson; Michael L Cleary; Chi Wai Eric So
Journal:  Nat Cell Biol       Date:  2007-09-23       Impact factor: 28.824

View more
  73 in total

1.  Optimization of High-Throughput Methyltransferase Assays for the Discovery of Small Molecule Inhibitors.

Authors:  Guangping Dong; Adam Yasgar; Darrell L Peterson; Alexey Zakharov; Daniel Talley; Ken Chih-Chien Cheng; Ajit Jadhav; Anton Simeonov; Rong Huang
Journal:  ACS Comb Sci       Date:  2020-06-27       Impact factor: 3.784

2.  Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.

Authors:  John R Horton; Clayton B Woodcock; Qin Chen; Xu Liu; Xing Zhang; John Shanks; Ganesha Rai; Bryan T Mott; Daniel J Jansen; Stephen C Kales; Mark J Henderson; Matthew Cyr; Katherine Pohida; Xin Hu; Pranav Shah; Xin Xu; Ajit Jadhav; David J Maloney; Matthew D Hall; Anton Simeonov; Haian Fu; Paula M Vertino; Xiaodong Cheng
Journal:  J Med Chem       Date:  2018-11-15       Impact factor: 7.446

3.  Probing the Plasticity in the Active Site of Protein N-terminal Methyltransferase 1 Using Bisubstrate Analogues.

Authors:  Dongxing Chen; Cheng Dong; Guangping Dong; Karthik Srinivasan; Jinrong Min; Nicholas Noinaj; Rong Huang
Journal:  J Med Chem       Date:  2020-07-16       Impact factor: 7.446

Review 4.  The critical role of histone lysine demethylase KDM2B in cancer.

Authors:  Meina Yan; Xinxin Yang; Hui Wang; Qixiang Shao
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

5.  Identification of the 2-Benzoxazol-2-yl-phenol Scaffold as New Hit for JMJD3 Inhibition.

Authors:  Assunta Giordano; Giovanni Forte; Stefania Terracciano; Alessandra Russo; Marina Sala; Maria C Scala; Catrine Johansson; Udo Oppermann; Raffaele Riccio; Ines Bruno; Simone Di Micco
Journal:  ACS Med Chem Lett       Date:  2019-02-25       Impact factor: 4.345

6.  Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.

Authors:  Yan Xiong; Fengling Li; Nicolas Babault; Hong Wu; Aiping Dong; Hong Zeng; Xin Chen; Cheryl H Arrowsmith; Peter J Brown; Jing Liu; Masoud Vedadi; Jian Jin
Journal:  Bioorg Med Chem       Date:  2017-06-19       Impact factor: 3.641

Review 7.  Recent progress in developing selective inhibitors of protein methyltransferases.

Authors:  H Ümit Kaniskan; Jian Jin
Journal:  Curr Opin Chem Biol       Date:  2017-06-26       Impact factor: 8.822

8.  Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor.

Authors:  Yudao Shen; Fengling Li; Magdalena M Szewczyk; Levon Halabelian; Kwang-Su Park; Irene Chau; Aiping Dong; Hong Zeng; He Chen; Fanye Meng; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Peter J Brown; Jing Liu; Masoud Vedadi; Jian Jin
Journal:  J Med Chem       Date:  2020-05-14       Impact factor: 7.446

9.  Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.

Authors:  Rossella Fioravanti; Annalisa Romanelli; Nicola Mautone; Elisabetta Di Bello; Annarita Rovere; Davide Corinti; Clemens Zwergel; Sergio Valente; Dante Rotili; Oronza A Botrugno; Paola Dessanti; Stefania Vultaggio; Paola Vianello; Anna Cappa; Claudia Binda; Andrea Mattevi; Saverio Minucci; Ciro Mercurio; Mario Varasi; Antonello Mai
Journal:  ChemMedChem       Date:  2020-02-14       Impact factor: 3.466

10.  Dual epigenetic modifiers for cancer therapy.

Authors:  Edurne San José-Enériz; Obdulia Rabal; Xabier Agirre; Julen Oyarzabal; Felipe Prosper
Journal:  Mol Cell Oncol       Date:  2017-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.